Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Hemi- and Central Retinal Vein Occlusion Associated with COVID-19 Infection in Young Patients without Known Risk Factors

Noy Ashkenazy, MD,1 Nimesh A. Patel, MD,1,2 Jayanth Sridhar, MD,4 Nicolas A. Yannuzzi, MD,7 Peter J. Belin, MD,3 Richard Kaplan, MD,4 Nikisha Kothari, MD,5 Gabriel A. Benitez Bajandas, MD,6 Radha P. Kohly, MD, PhD,7,8 Roberto Roizenblatt, MD, PhD,9 Alexander Pinhas, MD,10 Rusdeep Mundae, MD,11 Richard B. Rosen, MD, MSc,10 Edwin H. Ryan Jr., MD, Allen Chiang, MD, Louis K. Chang, MD, PhD,13 Rahul N. Khurana, MD,13,14 Avni P. Finn, MD, MBA13,15

Purpose: Venous thromboembolic complications have been reported in association with coronavirus disease 2019 (COVID-19) infection. We raised awareness regarding a potential temporal association between COVID-19 infection and retinal vein occlusion (RVO).

Design: Multicenter, retrospective, nonconsecutive case series.

Subjects: Patients presenting with hemi-RVO (HRVO) or central RVO (CRVO) between March 2020 and March 2021, with confirmed COVID-19 infection, were included. The exclusion criteria were as follows: age > 50 years, hypertension, diabetes, glaucoma, obesity, underlying hypercoagulable states, and those requiring intubation during hospitalization.

Methods: This was a multicenter, retrospective, nonconsecutive case series including patients presenting with hemi-RVO (HRVO) or central RVO (CRVO) between March 2020 and March 2021, with confirmed COVID-19 infection. The exclusion criteria were as follows: age > 50 years, hypertension, diabetes, glaucoma, obesity, underlying hypercoagulable states, and those requiring intubation during hospitalization.

Main Outcome Measures: Ophthalmic findings, including presenting and final visual acuity (VA), imaging findings, and clinical course.

Results: Twelve eyes of 12 patients with CRVO (9 of 12) or HRVO (3 of 12) after COVID-19 infection were included. The median age was 32 years (range, 18–50 years). Three patients were hospitalized, but none were intubated. The median time from COVID-19 diagnosis to ophthalmic symptoms was 6.9 weeks. The presenting VA ranged from 20/20 to counting fingers, with over half (7 of 12) having a VA of 20/40. OCT revealed macular edema in 42% of the eyes; of these, 80% (4 of 5) were treated with anti-VEGF injections. Ninety-two percent (11 of 12) had partial or complete resolution of ocular findings at final follow-up. Four eyes (33%) had retinal thinning, as determined using OCT, by the end of the study interval. The final VA ranged from 20/20 to 20/60, with 11 of the 12 (92%) eyes achieving a VA of 20/40 at a median final follow-up period of 13 weeks (range, 4–52 weeks).

Conclusions: Although we acknowledge the high seroprevalence of COVID-19 and that a causal relationship cannot be established, we reported this series to raise awareness regarding the potential risk of retinal vascular events due to a heightened thromboinflammatory state associated with COVID-19 infection. Ophthalmology Retina 2022;6:520-530 © 2022 by the American Academy of Ophthalmology

Coronavirus disease 2019 (COVID-19), an illness caused by severe acute respiratory syndrome coronavirus 2, is characterized by a spectrum of multiorgan clinical manifestations. The virus enters the host immune cells by fusing with the angiotensin-converting enzyme 2 receptor concentrated in the lungs, heart, intestines, arteries, and veins. The common symptoms of COVID-19 infection include fever, myalgias, dry cough, pharyngitis, dyspnea, and anosmia, but severe disease can progress to acute respiratory distress syndrome, sepsis, multiorgan failure, and death.

Although COVID-19 is primarily a respiratory illness, there has been emerging data indicating that coagulation dysfunction associated with the virus predisposes the patients to arterial and venous thromboembolic events. A meta-analysis of 425 studies showed an overall venous thromboembolic rate of 21% in patients with COVID-19, and this rate was even higher in patients in the intensive care unit. The hypercoagulable state associated with COVID-19 is thought to be multifactorial and associated with the activation of the fibrinolytic pathway, a “cytokine” storm, and viral-mediated endothelial damage. These coagulation abnormalities associated with COVID-19 are distinct from those associated with severe infections such as disseminated intravascular coagulopathy or thrombotic...
microangiopathy. Specifically, thrombocytopenia is not as profound as that associated with disseminated intravascular coagulopathy, and the D-dimer level is markedly higher with COVID-19. Given this, it is plausible that this so-called “COVID-19—associated coagulopathy” increases the risk of diagnosing retinal vascular abnormalities.

Moreover, recent literature has expanded the potential clinical spectrum of COVID-19 infection. The ocular manifestations reported in the literature to date include conjunctivitis, retinal microangiopathy, paracentral acute middle maculopathy, acute macular neuroretinopathy, uveitis, and optic neuropathy. Additionally, multiple reports describing retinal vascular events, such as central retinal artery occlusions, branch retinal vein occlusions (BRVOs), hemiretinal vein occlusion (HRVO), central retinal vein occlusion (CRVO), papillitis, and papillophlebitis, after the diagnosis of COVID-19 have been published. The series presented herein expands on the literature and aims to highlight a potential temporal association between COVID-19 infection and the development of retinal vein occlusions (RVOs) in otherwise young, healthy patients without other risk factors for RVO.

Methods

This was a multicenter, retrospective, nonconsecutive case series. Individual case contributors across the United States provided relevant information about eligible cases based on diagnostic criteria. Cases from each respective institution were identified using a local survey of known RVO cases occurring after confirmed COVID-19 infection. Information about each case was obtained from a review of medical records at each participation site. The participating sites included the following: Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida; Massachusetts Eye and Ear Infirmary, Harvard University, Boston, Massachusetts; VitreoRetinal Surgery, PLLC, Minneapolis, Minnesota; Connecticut Retina Consultants, Fairfield, Connecticut; Texas Retina Associates, Dallas, Texas; Eastern Retina Consultants of Puerto Rico Psc, Humacao, Puerto Rico; Department of Ophthalmology, Sunnybrook Health Sciences Center, Toronto, Canada; Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada; South Coast Retina Center, Long Beach, California; New York Eye and Ear Infirmary of Mount Sinai, New York, New York; Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota; Mid Atlantic Retina, Wills Eye Hospital Retina Service, Philadelphia, Pennsylvania; Northern California Retina Vitreous Associates, Mountain View, California; and Department of Ophthalmology, University of California, San Francisco, California. This study received approval from the institutional review board at University of Miami Miller School of Medicine and was conducted after the approval of the Human Subjects Committee. Our research methods adhered to the tenets of the Declaration of Helsinki and were compliant with the Health Insurance Portability and Accountability Act. All participants provided informed consent.

We included patients aged >5 years diagnosed with HRVO or CRVO between March 2020 and March 2021 and presenting within 18 weeks of COVID-19 infection. Only patients who underwent a hypercoagulable workup to exclude any pre-existing thrombophilia (e.g., including prothrombin time, partial thromboplastin time, antithrombin III, and homocysteine) were included. Patients aged >50 years and those with comorbidities, including hypertension, diabetes, cardiovascular disease, glaucoma, obesity, and underlying hypercoagulability, determined based on a laboratory evaluation, were excluded. Patients with other types of pathology, such as arterial occlusions, BRVOs, and optic neuropathy, and patients requiring intubation or positive-pressure ventilation (i.e., continuous positive airway pressure or intubation) during hospitalization for COVID-19 infection, were excluded.

After reviewing 22 collected cases, 12 eyes of 12 patients were included in the series. One case that was previously published by 2 coauthors of the present series (R.N.K. and A.P.F.), was included. We excluded 3 patients with BRVOs, 1 with a central retinal artery occlusion, and 4 who were aged >50 years and had confounding comorbidities. Two others were excluded because their laboratory evaluation result was positive for inherent hypercoagulability (1 with a MTHFR homozygous mutation and another positive for anticardiolipin and borderline lupus anticoagulant antibodies).

Only patients with CRVO and HRVO were included in this study because the pathophysiology is thought to be strongly related to hypercoagulability and venous injury, with occlusion occurring at the level of the lamina cribrosa. In contrast, the authors excluded patients with BRVO because it is thought to result from mechanical venous compression of an adjacent thick-walled artery, more likely in the setting of chronic vascular risk factors. Patients with arterial occlusions and those with underlying coagulopathies were excluded because of complex mechanisms that do not directly correspond with the concepts of the Virchow triad.

Patient charts were reviewed by individual case contributors for information regarding patient demographics, ophthalmic findings, imaging studies, diagnoses, treatments, clinical course, and medical history. Statistical analyses were performed using the SPSS 25.0 (SPSS Inc) software package. Mean, median, mode, and range were used to present descriptive statistics.

Results

The clinical characteristics of the 12 eyes of 12 patients in our study are summarized in Table 1. All the patients tested positive for COVID-19 infection (91.7%, 11 of 12 confirmed using reverse transcriptase polymerase chain reaction and 1 of 12 confirmed using an unknown method), none were intubated, and none were known to have an underlying coagulopathy. Of the 12 cases, 75% (9 of 12) had CRVO and 25% (3 of 12) had HRVO. The median age at presentation was 32 years (range, 18–50 years). Twenty-five percent (3 of 12) were hospitalized for COVID-19 management. The median time from COVID-19 diagnosis to ocular symptoms was 6.9 weeks (range, 1–13 weeks), with a median of 10.5 days (range, 1–42 days) of reported symptoms before ophthalmic diagnosis. Six (50%) patients had ocular symptoms within 1 month of the viral infection. The median follow-up duration in our cohort was 13 weeks (range, 4–52 weeks).

Most eyes did not develop macular edema at any point throughout follow-up. Macular edema developed in 42% (5 of 12) of the eyes; in 80% (4 of 5) of these cases, macular edema was noted at presentation, and 1 developed macular edema at 6 weeks of follow-up and 9 weeks after the diagnosis of COVID-19 infection (Fig 1).

The presenting visual acuity (VA) ranged from 20/20 to counting fingers, with 58% of the eyes (7 of 12) having an initial
| Case # | Age (yrs) | Gender (M/F) | Race/ Ethnicity | Diagnosis | COVID-19 Test | Hospitalized | Duration of Symptoms Prior to Exam (days) | Time from Systemic to Ocular Diagnosis (weeks) | Macular Edema at Presentation | Treatment after RVO | VA Initial | VA Final | Final OCT Status | Follow Up (weeks) |
|--------|-----------|--------------|-----------------|-----------|---------------|--------------|------------------------------------------|-----------------------------------------------|-------------------------------------------|----------------------|------------|----------|-----------------|------------------|
| 1      | 33        | M            | White           | HRVO      | RT-PCR        | No           | 21                                        | 6                                             | No                         | None                 | 20/20     | 20/15    | Thin             | 24               |
| 2      | 29        | M            | Hispanic        | CRVO      | RT-PCR        | Yes          | 7                                         | 12                                            | Yes - massive CME          | Bevacizumab (1)     | 20/80     | 20/20   | Normal [10]     | 11               |
| 3      | 24        | F            | White           | CRVO      | RT-PCR        | No           | 2                                         | 4                                             | No                         | None                 | 20/60     | 20/30    | Thin             | 22               |
| 4      | 36        | F            | White           | CRVO      | RT-PCR        | No           | 21                                        | 14                                            | Yes - massive CME          | Bevacizumab (3)     | 20/70     | 20/20   | Normal [4]      | 9                |
| 5      | 22        | M            | White           | CRVO      | Unknown method | No           | 7                                         | 9                                             | Yes - mild CME            | None                 | 20/20     | 20/20   | Normal [4]      | 4                |
| 6      | 18        | F            | Black           | HRVO      | RT-PCR        | No           | 14                                        | 3                                             | No                         | None                 | 20/25     | 20/20   | Normal           | 15               |
| 7      | 50        | F            | Hispanic        | CRVO      | RT-PCR        | Yes          | 32                                        | 18                                            | No                         | Plavix               | 20/30     | 20/25   | Normal           | 21               |
| 8      | 41        | F            | Black           | HRVO      | RT-PCR        | Yes          | 14                                        | 15                                            | No                         | None                 | 20/50     | 20/30   | Thin             | 10               |
| 9      | 34        | M            | White           | CRVO      | RT-PCR        | No           | 42                                        | 14                                            | No                         | None                 | 20/20     | 20/20   | Normal           | 6                |
| 10     | 30        | M            | White           | CRVO      | RT-PCR        | No           | 1                                         | 6                                             | Yes - massive CME          | Prednisone PO Bevacizumab (1) | 20/20     | 20/20   | Thin [6]         | 52               |
| 11     | 31        | F            | Hispanic        | CRVO      | RT-PCR        | No           | 1                                         | 1                                             | No                         | None                 | 20/20     | 20/20   | Normal           | 33               |
| 12     | 38        | F            | White           | CRVO      | RT-PCR        | No           | 7                                         | 4                                             | No - delayed CME           | Bevacizumab (2)     | 20/20     | 20/60   | CME              | 11               |

Key: CME = cystoid macular edema; COVID-19 = coronavirus disease 2019; CRVO = central retinal vein occlusion; F = female; HRVO = hemiretinal vein occlusion; M = male; PO = oral administration; RVO = retinal vein occlusion; RT-PCR = real-time polymerase chain reaction; VA = visual acuity (Snellen). () indicates number of intravitreal injections throughout follow up course; [] indicates time to resolution of macular edema.
VA of ≥20/40. Macular edema was associated with a poorer presenting VA, as illustrated in Figure 2. Four cases were treated with anti-VEGF injections (range, 1–3 total injections) for macular edema, identified using OCT, and the remaining case was observed. The standard dosage of the intravitreal bevacizumab injections was 1.25 mg/0.05 mL.

There was partial or complete resolution of RVO in 92% (11 of 12) of the eyes of patients with confirmed COVID-19 infection at final follow-up, as illustrated in Figure 3. Although most patients did not require systemic treatment with anticoagulation, 17% (2 of 12) were treated with antiplatelet therapy at the time of CRVO, 1 of whom was also treated with high-dose oral prednisone (Table 1).

Figure 1. Clinical response to intravitreal anti-VEGF therapy for the treatment of macular edema associated with central retinal vein occlusion after coronavirus disease 2019 infection. A, OCT (Heidelberg Spectralis) of the right eye in case 4 showed macular edema (top), which resolved (bottom) following treatment with 3-monthly intravitreal bevacizumab (Avastin, Genentech) injections. B, OCT of the left eye in case 12 lacked macular edema at presentation (top) but developed macular edema at week 6. Macular edema was persistent despite the administration of 2 intravitreal bevacizumab injections at weeks 6 (middle) and 11 (bottom).

Figure 2. Right eye in case 10 presenting with central retinal vein occlusion (CRVO) following coronavirus disease 2019 infection. A, A fundus photograph (Optos) shows intraretinal hemorrhages in all quadrants, a flame hemorrhage off the disc, and tortuous vessels, consistent with CRVO. B, Fluorescein angiography (Optos) shows delayed peripheral perfusion and diffuse small-vessel leakage. C, D, The presenting OCT (Heidelberg Spectralis) (C) showed massive cystoid macular edema, which improved (D) just 1 week after treatment with a single intravitreal bevacizumab (Avastin, Genentech) injection. There was complete resolution of macular edema and the development of residual retinal thinning, as determined using OCT (not shown), by 52 weeks of follow-up.
Most eyes maintained good VA throughout the follow-up interval. The final VA ranged from 20/20 to 20/60. Ninety-two percent (11 of 12) of the eyes achieved a final vision of 20/30 or better. The vision in some eyes that lacked macular edema improved as the vascular occlusive event resolved (Fig 4). Four eyes had retinal thinning, determined using OCT, at final follow-up (Table 1).

Discussion

Coagulopathy in the setting of COVID-19 infection has been well reported in the general medical literature. COVID-19 causes the activation of the fibrinolytic pathway, leading to increased fibrinogen, D-dimer, and prothrombin time; decreased platelets; and, in some cases, rebound thrombocytosis.3,5 Proinflammatory cytokines are also released, and these contribute to a generalized prothrombotic milieu.42

The pathogenesis of CRVO or HRVO is believed to be secondary to the Virchow triad as well as compression in the shared venous and arterial adventitial sheath at the level of the lamina cribrosa.38 Similarly, the pathophysiology of venous thromboembolism following COVID-19 infection is suspected to be related to a combination of inflammation, endothelial injury, vascular stasis, and coagulopathic risk factors.37 The interplay of tissue hypoperfusion as well as vascular injury, thrombosis, and dysfunction explains the thromboembolic state in patients with COVID-19.43,44 This may be a result of direct viral damage to the endothelium as well as the activation of endothelial and immune cells by a cytokine storm. Direct viral-mediated endothelial injury in the setting of RVO following COVID-19 infection was supported by studies that isolated severe acute respiratory syndrome coronavirus 2 from ocular tissues. Viral RNA was sequestered from the tears of infected patients in up to 7% of cases.45,46 Casagrande et al.46 reported that severe acute respiratory coronavirus 2 RNA was detected in the retina of 3 of 14 deceased patients with COVID-19 using polymerase chain reaction at the time of autopsy. Furthermore, Araujo-Silva et al47 illustrated the findings of presumed viral particles within the retina of 3 deceased patients with COVID-19.

Multiple studies have described retinal microangiopathy, commonly, cotton wool spots and small intraretinal hemorrhages, in patients with COVID-19.11–17 Sim et al.12 in their prospective, cross-sectional analysis of 216 eyes of 108 patients who tested positive for COVID-19, showed that 1 in 9 (11.6%) patients had signs of retinal microvascular disease. The authors observed that there was no significant

Figure 3. Right eye in case 2 presenting with central retinal vein occlusion following coronavirus disease 2019 infection. A, A fundus photograph (Optos) shows diffuse intraretinal hemorrhages and dilated, tortuous venules at presentation. B, Fluorescein angiography (Optos, UK) shows diffuse vascular leakage in late phases. C, Fundus abnormalities (Topcon) resolved 10 weeks later. D and E, Initial OCT (Heidelberg Spectralis) showed cystoid macular edema (D), which resolved by 10 weeks of follow-up (E) after treatment with 1 intravitreal bevacizumab (Avastin, Genentech) injection.
difference in the presence of microangiopathy between the groups of patients with symptomatic and asymptomatic COVID-19. The retinal vascular changes were attributed to cardiovascular and thrombotic alterations related to the viral infection. Abrishami et al.\(^{14}\) reported that patients who had recovered from COVID-19 had alterations in their retinal microvasculature, as seen using OCT angiography, compared with healthy controls. They reported an increased retinal vessel diameter and decreased vascular density in the superficial and deep capillary plexuses in these patients. Furthermore, a meta-analysis by Sen et al.\(^{13}\) concluded that in 15 included articles, both sick and healthy patients with COVID-19 developed retinal vascular disease.

Our study identified that most patients with CRVO occurring after COVID-19 infection presented for their eye examination within weeks of a positive viral test result. The most delayed case in this series was the patient in case 9, who presented with CRVO at 18 weeks after the infection after a 4-week delay in ophthalmic evaluation from symptom onset. Consistent with the findings in our study, Von Meijenfeld et al.\(^{44}\) showed that the prothrombotic state may last up to 4 months after COVID-19 infection. Because of the subjective nature of ocular symptoms, it is difficult to determine when a CRVO event truly occurs in relation to the onset of systemic infection. Our study findings highlight the importance of having a high clinical suspicion for a vascular event at the onset of ocular symptoms to minimize delay in care.

To date, retinal vascular occlusions occurring after COVID-19 infection have been limited to case reports and are, likely, very rare. Various authors have described retinal vascular occlusions, including central retinal artery occlusion, BRVOs, and CRVOs, in association with COVID-19 (Table 2).\(^{22-37}\) The present report is the largest case series of CRVO and HRVO occurring after COVID-19 infection. It nearly doubles the currently published cases in the literature and is the only 1 to exclude predisposing risk factors. Furthermore, we performed a complete literature review of all previously published cases.

Of 12 previously published reports (13 eyes) of CRVOs or HRVOs after COVID-19 infection in the literature, half lacked predisposing conditions.\(^{37}\) Similar to our cohort, the VA outcomes were favorable, with most patients achieving a Snellen acuity of 20/40 or better. Macular edema was identified and treated with intravitreal injections in the 46% (6 of 13) of the eyes in the published cases of HRVO or CRVO after COVID-19 infection. Similarly, our study showed that 42% (5 of 12) of the eyes developed macular edema. Based on the Central Vein Occlusion Study, in which the angiographic evidence of macular edema occurred in 84% of eyes with CRVO,\(^{48}\) it is possible that macular edema occurs at a lesser frequency in patients with CRVO after COVID-19 infection. Alternatively, young patients have previously been reported to have better visual outcomes and lower rates of macular edema.\(^{49,50}\) As such, age may simply be a driver of these prognostic factors in our series. Although a statistical analysis of a larger cohort would be necessary to draw this conclusion, we hypothesize that this is related to the transient nature of the prothrombotic state following the
| Study                  | Patient Age, Gender | Comorbid Dx | Hospitalized, Oxygen, Complication | Ocular Dx | Time to Ocular Dx | Hypercoagulable work-up | Treatment                                                                 | Visual Acuity (initial) | Visual Acuity (final) | Follow Up |
|-----------------------|---------------------|-------------|----------------------------------|-----------|------------------|-------------------------|---------------------------------------------------------------------------|-------------------------|----------------------|-----------|
| **Central retinal artery occlusions** |                     |             |                                  |           |                  |                         |                                                                          |                         |                      |           |
| Acharya (2020)        | 60, F               | Y-HTN, HL, CAD, COPD | Y, intubated                    | CRAO, OD  | 12 d             | IL6, CRP, ferritin, fibrinogen, D-dimer (H) | Hydroxychloroquine Azithromycin Tocilizumab                              | N/A                     | N/A                  | N/A       |
| Montesel (2020)       | 59, M               | Y-HTN, hyperuricemia Sickle cell trait | Y, intubated                    | CRAO, OS Sickle cell retinopathy (sea fans) | 3-4 wks | IL6, IL7, CRP, fibrinogen, D-dimer, PTT (H) | Hydroxychloroquine Azithromycin Tocilizumab 800 mg Lopinavir/Ritonavir (200/50 mg) BID LMWH, Apixaban | LP CF 1 mo |
| Murchison (2020)      | 50s, M              | N           | Y, for ocular dx only, no O2     | CRAO, OD  | 2-3 d             | PT, INR, D-dimer, fibrinogen, lactate, CRP (H) Negative | Hydroxychloroquine Azithromycin Tocilizumab 800 mg Lopinavir/Ritonavir (200/50 mg) BID LMWH, Apixaban | HM N/A N/A |
| Turedi (2021)         | 54, M               | N           | Y, no O2                        | CRAO, OD  | 14 d             | Unknown                                                        | Hyperbaric oxygen CF CF 5 d |                       |           |
| Montesel (2020)       | 59, M               | Y-HTN, hyperuricemia Sickle cell trait | Y, intubated                    | CRAO, OS Sickle cell retinopathy (sea fans) | 3-4 wks | IL6, IL7, CRP, fibrinogen, D-dimer, PTT (H) | Hydroxychloroquine Azithromycin Tocilizumab 800 mg Lopinavir/Ritonavir (200/50 mg) BID LMWH, Apixaban | LP CF 1 mo |
| **Branched retinal vein occlusions (BRVO)** |                     |             |                                  |           |                 |                         |                                                                          |                         |                      |           |
| Duff (2020)           | 74, F               | Y-HL        | N                                | BRVO, OS CME | <1 wk, worse at 3 mo | Unknown                                                        | IVI Dex implant 20/25 | N/A                  | N/A       |
| Nourinia (2021)       | 60, F               | N           | Y, ICU, O2 unknown               | BRVO, OS CME | 10 d             | ESR, CRP, ferritin, WBC, PTT, PT (H) | IVI Bevacizumab 20/200 | N/A                  | N/A       |
| **Central retinal vein occlusions** |                     |             |                                  |           |                  |                         |                                                                          |                         |                      |           |
| Gaba (2020)           | 40, M               | Y-HTN, obesity | Y, O2 NC, DVT                   | CRVO, OU  | 2 d              | IL-6, CRP, ferritin, D-dimer, lactate (H) | Rivaroxaban Observation IV Solumedrol PO Prednisone Observation | 6/6 OD 6/12 OS | N/A                  | N/A       |
| Invernizzi (2020)     | 54, F               | N/A         | Y, for ocular tx only, No O2     | CRVO, OD  | 10 d             | CRP, ESR, lactate, D-dimer, fibrinogen, INR (H) | Observation | 20/40 | 20/20 1 wk |
| Yahalomi (2020)       | 33, M               | N           | Y, N/A                          | CRVO, OS CRVO, OU | 5 wks | N/A | Fibrinogen, D-dimer (H) CRP, fibrinogen, ferritin, D-dimer, platelets (H) | Observation | 20/25 N/A N/A N/A |
| Lorca (2020)          | 30, F               | Y-DM (A1c 13%) | N                                | CRVO CME  | 1 mo             | Negative | Antibx, NSAIDS IVI Ranibizumab(x2) IVI Aflibercept 20/20, then 20/80 (11 d) | 6/24 6/12 2 mo |
| Walunjkar (2020)      | 17, M               | N           | N                                | CRVO CME  | 3 wks             | Negative | N/A | 0.7 | N/A N/A N/A |
| Miller (2021)         | 46, M               | Y-HTN, HL   | N                                | CRVO, OD CME | 1 wk | Negative | IVI Bevacizumab (>1) | 20/20, then 20/80 (11 d) 20/150 | 20/30 N/A |
| Raval (2021)          | 39, M               | N           | N/A                             | CRVO, OD CME | 1 wk | Negative | IVI Bevacizumab (>1) | 20/20, then 20/80 (11 d) 20/150 | 20/30 N/A |
Table 2. (Continued.)

| Patient | Hospitalized, Comorbid Dx | Visual Acuity Follow-up | Visual Acuity (initial) | Time to Hyperc当地able work-up | Treatment |
|---------|----------------------------|-------------------------|-------------------------|-----------------------------|-----------|
| Sanchez (2021) | 32, M | N | N | CRVO, OD | 8 wks | ASA 150 mg/d, Observation |
| Venkatesh (2021) | 54, F | DM (controlled) | N-asymptomatic | CRVO, OS | >1 mo | D-dimer, ASA 150 mg/d, Observation |
| Insausti-Garcia (2020) | 40, M | N | N | Papillophlebitis, OS | 6 wk | D-dimer, ASA 150 mg/d, Observation |
| Sheth (2020) | 52, M | N/A | Y, N/A | HRVO, OS | 10 d | Negative PO Solumedrol |

Key: Age: <65 years; Gender: F = female; M = male; wks = weeks; mo = month; yrs = years; N = no; Y = yes; CRVO = central retinal vein occlusion; HRVO = hemiretinal vein occlusion; PO = oral; IVI = intravitreal; IV = intravenous; PTT = partial thromboplastin time; WBC = white blood cell; U = urine; OD = right eye; OS = left eye; OU = both eyes; CME = cystoid macular edema; DVT = deep vein thrombosis; D-dimer = D-dimer; ESR = erythrocyte sedimentation rate; ASA = aspirin; CRP = C-reactive protein; CAD = coronary artery disease; COPD = chronic obstructive pulmonary disease; COVID-19 = coronavirus disease 2019; CRVO = central retinal vein occlusion; HRVO = hemiretinal vein occlusion; ICUs = intensive care units; LMWH = low molecular-weight heparin; NSAIDS = nonsteroidal anti-inflammatory drugs; PTT = partial thromboplastin time; P = prothrombin time; PT = prothrombin time; PC = protein C; PS = protein S; NS = not specified; OC = ocular; tobacco use; alcohol use; hypertension; glaucoma; barbiturate use; and abnormal serum creatinine, phosphorus, ionized calcium levels; VAs = vascular disease, medications (oral contraceptives, diuretics, may be linked to smoking, migraine headaches, collagen vascular disease, diabetes mellitus); and biomarkers known to be associated with COVID-19. Other studies have identified that CRVO in young adults may be linked to smoking, migraine headaches, collagen vascular disease, medications (oral contraceptives, diuretics, and sympathomimetics), and thrombophilia.

Ashkenazy et al · RVO after COVID-19 Infection

Young adults presenting with RVO may need a hypercoagulability workup to exclude systemic coagulopathies requiring anticoagulation, such as protein C and S deficiency, factor V Leiden mutation, hyperhomocysteinemia, antiphospholipid antibody syndrome, prothrombin gene mutation, antithrombin deficiency, and hyperviscosity syndrome, among others. The patients included in the present series were negative for thrombophilia, as determined using extensive laboratory evaluations performed by the contributing ophthalmologists and appropriate medical providers. Additionally, given the known coagulation abnormalities associated with COVID-19, we recommend that the D-dimer, fibrinogen, and platelet levels are measured at the time of diagnosis.

Our study has a number of limitations, including a retrospective, nonconsecutive design; small cohort size; and lack of standardized methods to account for all risk factors and biomarkers known to be associated with COVID-19 infection. The study design and low sample size do not support COVID-19 as being an independent risk factor for RVO development. The retrospective design did not allow us to control for all components of a thrombophilia evaluation, and thus, this was deferred to the expertise of the contributing ophthalmology provider and medical consultants. The study design could not account for confounding variables and other risk factors outside of our defined exclusion criteria. The timing of patients presenting for an ophthalmic examination after COVID-19 infection might vary, and this could influence the results of the hypercoagulability workup. This information would be important in determining the frequency and duration of follow-up for these cases.

The true prevalence of COVID-19 among patients with RVO is unknown. Sunny and Au reported that in their cohort of 66 patients with CRVO, the dominant risk factors were hypertension, diabetes, and hyperlipidemia, and no patients were positive for COVID-19 infection at presentation through a mean follow-up duration of 5.8 months. There are currently no large-scale studies assessing the rate of RVOs in a population of patients diagnosed with COVID-19.

The present study excluded patients with well-defined risk factors for the development of RVOs (Table 1). Generally, RVOs are much less common in patients aged <65 years, in the absence of systemic risk factors. The Beaver Dam Eye Study identified the following risk factors for RVO formation: older age; retinal focal arteriolar narrowing; glaucoma; barbiturate use; and abnormal serum creatinine, phosphorus, ionized calcium levels. In contrast, the risk factors for young adults developing RVOs are multifactorial and less understood. In a series of 95 patients diagnosed with CRVO between 18 and 40 years of age, Chen et al identified that the statistically significant (\( P < 0.001 \)) risk factors for CRVO in young adults included primary open-angle glaucoma, retinal vasculitis, pseudotumor cerebri, hypercoagulable state, hyperlipidemia, and a prior history of venous thromboembolic disease. Other studies have identified that CRVO in young adults may be linked to smoking, migraine headaches, collagen vascular disease, medications (oral contraceptives, diuretics, and sympathomimetics), and thrombophilia.
have resulted from heightened personal awareness of symptoms following the illness, resulting in a selection bias in our study. Importantly, large, multicenter, controlled studies are needed to compare the RVO rates among young patients with and without recent COVID-19 infection.

**Conclusion**

Although we acknowledge that a high seroprevalence of COVID-19 exists and that a causal relationship between COVID-19 and CRVO cannot be established, patients and physicians should be aware of this association, given the heightened thromboinflammatory state caused by COVID-19 infection. Our series showed that in young, healthy patients with CRVO after COVID-19 infection, there was a possible temporal association with ocular symptoms typically occurring within weeks after the viral infection. Although the relationship remains anecdotal, patients may benefit from the reassurance that, like other RVOs occurring in patients of their age group, their condition is episodic and the prognosis is typically favorable with minimal intervention.

**Footnotes and Disclosures**

Originally received: December 8, 2021.
Final revision: February 8, 2022.
Accepted: February 11, 2022.
Available online: March 10, 2022. Manuscript no. ORET-D-21-00704R2

1 Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Miami, Florida.
2 Massachusetts Eye and Ear Infirmary, Harvard University, Boston, Massachusetts.
3 VitreoRetinal Surgery, PLLC, Minneapolis, Minnesota.
4 Connecticut Retina Consultants, Fairfield, Connecticut.
5 Texas Retina Associates, Dallas, Texas.
6 Eastern Retina Consultants of Puerto Rico Psc, Humacao, Puerto Rico.
7 Department of Ophthalmology, Houston Veterans Affairs Medical Center.
8 Department of Ophthalmology and Vision Sciences, University of Toronto, Ontario, Canada.
9 Department of Ophthalmology and Vision Sciences, University of Toronto, Toronto, Canada.
10 South Coast Retina Center, Long Beach, California.
11 Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis, Minnesota.
12 Mid Atlantic Retina, Wills Eye Hospital Retina Service, Philadelphia, Pennsylvania.
13 Northern California Retina Vitreous Associates, Mountain View, California.
14 Department of Ophthalmology, University of California, San Francisco, California.
15 Department of Ophthalmology, Vanderbilt University, Nashville, Tennessee.

Presented as a Paper-On-Demand for the American Society of Retina Specialists Annual Meeting October 8-12, 2021, San Antonio, TX (Dr Ashkenazy) as well as an oral presentation at the Retina Society Annual Meeting September 29-October 2, 2021, Chicago IL (Dr Finn).

Disclosure(s):
All authors have completed and submitted the ICMJE disclosures form.
The authors made the following disclosures: N.A.: Advisory Board — Alimera Sciences.
N.A.P.: Consultant — Allergan, Alimera Sciences, Alcon, Genentech, Guardant, Maples Sciences, Lifesciences, Eye Point.
J.S.: Consultant — Alcon; Advisory Board — Allergan, Oxurion; Consultant — DORC, Genentech, Regeneron.
N.A.Y.: Advisory Board — Alcon, Genentech, Regenxbio.
R.B.R.: Consultant — Optovue, CellView, Boehringer-Ingelhelm, Astellas, US patent #WO 2016/109750 AI, 43625.140US01, Optovue; Stock — Guardion; Services — Optovue.
A.C.: Advisory Board — Genentech (clinical trial support for RHINE/ RHONE-X studies), Genentech/Roche (medical writing, post hoc study DRCR Protocol S).
R.N.K.: Consultant — Allergan, Apellis, Genentech, Alkastem, Regeneron, Merck, Bausch & Lomb; Advisory Board — Clearside Biomedical, Aerie.
A.P.F.: Advisory Board — Allergan, Genentech; Consultant — Apellis pharmaceuticals.

Supported in part by the National Institutes of Health Center Core Grant P30EY014801 (Bethesda, Maryland), Research to Prevent Blindness Unrestricted Grant (GR004596) to the University of Miami.

HUMAN SUBJECTS: Human subjects were included in this study. This study received approval from the institutional review board at the University of Miami Miller School of Medicine and was conducted after the approval of the Human Subjects Committee. All research complied with the Health Insurance Portability and Accountability Act of 1996 and adhered to the tenets of the Declaration of Helsinki. All participants provided informed consent. No animal subjects were included in this study.

Author Contributions:
Conception and design: Ashkenazy, Patel, Sridhar, Yannuzzi, Khurana, Finn
Analysis and interpretation: Ashkenazy, Finn
Data collection: Ashkenazy, Patel, Sridhar, Yannuzzi, Belin, Kaplan, Kothari, Bajandas, Kohly, Roizenblatt, Pinhas, Mundae, Rosen, Ryan, Chang, Chiang, Khurana, Finn
Obtained funding: N/A
Overall responsibility: Ashkenazy, Patel, Sridhar, Yannuzzi, Belin, Kaplan, Kothari, Bajandas, Kohly, Roizenblatt, Pinhas, Mundae, Rosen, Ryan, Chang, Chiang, Khurana, Finn

Abbreviations and Acronyms:
BRVO = branch retinal vein occlusion; COVID-19 = coronavirus disease 2019; CRVO = central retinal vein occlusion; HRVO = hemiretinal vein occlusion; RVO = retinal vein occlusion; VA = visual acuity.

Keywords:
COVID-19, Macular edema, Retinal vascular disease, Retinal vein occlusion, Venous thromboembolism.

Correspondence:
Avni P. Finn, MD, MBA, Department of Ophthalmology, Vanderbilt University Medical Center, 2311 Pierce Ave, Nashville, TN 37212. E-mail: Avni.finn@vumc.org.
References

1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72,314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323:1239–1242.

2. Davidson AM, Wysocki J, Batlle D. Interaction of SARS-CoV-2 and other coronavirus with ACE (angiotensin-converting enzyme)-2 as their main receptor: therapeutic implications. Hypertension. 2020;76:1339–1349.

3. Levi M, Thachil J, Iba T, Levy JH. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7:e438–e440.

4. Connors JM, Levy JH. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–2040.

5. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–847.

6. Middeldorp S, Coppens M, van Haaps TF, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and metaanalysis. EClinicalmedicine. 2020;29:100639.

7. Malas MB, Nazzie IN, Elsayed N, et al. Thromboembolism risk of COVID-19 is high and associated with a higher risk of mortality: a systematic review and metaanalysis. EClinicalmedicine. 2020;29:100639.

8. Belen-Apak FB, Sarı RM, Pan T, et al. Pulmonary intravascular coagulation in COVID-19: possible pathogenesis and recommendations on anticoagulant/thrombolytic therapy. J Thromb Thrombolysis. 2020;50:278–280.

9. Franchini M, Marano G, Cruciani M, et al. COVID-19-associated coagulopathy. Diagnosis (Berl). 2020;7:357–363.

10. Wong RL, Ting DS, Wan KH, et al. COVID-19: ocular manifestations and the APAO prevention guidelines for ophthalmic practices. Asia Pac J Ophthalmol (Phila). 2020;9:281–284.

11. Gascon P, Briantais A, Bertrand E, et al. COVID-19-associated retinopathy: a case report. Ocul Immunol Inflamm. 2020;28:1293–1297.

12. Sim R, Cheung G, Ting D, et al. Retinal microvascular signs in COVID-19. Br J Ophthalmol. 2021 Mar 19;bjojophthal-2020-318236. doi: 10.1136/bjojophthal-2020-318236. Online ahead of print.

13. Sen S, Kannan NB, Kumar J, et al. Retinal manifestations in patients with SARS-CoV-2 infection and pathogenetic implications: a systematic review. Int Ophthalmol. 2022;42:323–336.

14. Abrishami M, Emanverdian Z, Shoiebi N, et al. Optical coherence tomography angiography analysis of the retina in patients recovered from COVID-19: a case-control study. Can J Ophthalmol. 2021;56:24–30.

15. Landecho MF, Yuste JR, Gándara E, et al. COVID-19 retinal microangiopathy as an in vivo biomarker of systemic vascular disease? J Intern Med. 2021;289:116–120.

16. Invernizzi A, Torre A, Parrilli S, et al. Retinal findings in patients with COVID-19: results from the SERPICO-19 study. EClinicalmedicine. 2020;27:100550.

17. Szkody D, Wylegala E, Sujka-Franczak P, et al. Retinal OCT findings in patients after COVID infection. J Clin Med. 2021;10:3233.

18. Virgo J, Mohamed M. Paracentral acute middle maculopathy and acute macular neuroretinopathy following SARS-CoV-2 infection. Eye (Lond). 2020;34:2352–2353.

19. Benito-Pascual B, Gégundez JA, Díaz-Valle D, et al. Panuveitis and optic neuritis as a possible initial presentation of the novel coronavirus disease 2019 (COVID-19). Ocul Immunol Inflamm. 2020;28:922–925.

20. Finsterer J, Scorza FA, Scorza CA, Fiorini AC. Vascular damage may mimic retinitis and optic neuritis in COVID-19. Curr Eye Res. 2021;46:1934–1935.

21. Sawalha K, Avedokun S, Kamoga GR. COVID-19-Induced acute bilateral optic neuritis. J Investig Med High Impact Case Rep. 2020;8:2324709620976018.

22. Acharya S, Diamond M, Anwar S, et al. Unique case of central retinal artery occlusion secondary to COVID-19 disease. IDCases. 2020;21:e00867.

23. Montesel A, Buccolo C, Mouvet V, et al. Case report: central retinal artery occlusion in a COVID-19 patient. Front Pharmacol. 2021;11:588384.

24. Murchison AP, Weid A, Dharia R, et al. Monocular visual loss as the presenting symptom of COVID-19 infection. Clin Neurol Neurosurg. 2021;201:106440.

25. Tureddi N, Onal Gunay B. Paracentral acute middle maculopathy in the setting of central retinal artery occlusion following COVID-19 diagnosis. Eur J Ophthalmol. 2021 Feb 14;12:120672121995347. doi: 10.1177/120672121995347. Online ahead of print.

26. Duff SM, Wilde M, Khurshid G. Branch retinal vein occlusion in a COVID-19 positive patient. Cureus. 2021;13:e13586.

27. Nourinia R, Ghassempour M, Ahmadieh H, Abtahi SH. Branch retinal vein occlusion after COVID-19. J Fr Phthal-alm. 2021;44:e441–e443.

28. Gaba WH, Ahmed D, Al Nuaimi RK, et al. Bilateral central retinal vein occlusion in a 40-year-old man with severe coronavirus disease 2019 (COVID-19) pneumonia. Am J Case Rep. 2020;21:e927691.

29. Sheth JU, Narayanan R, Goyal J, Goyal V. Retinal vein occlusion in COVID-19: a novel entity. Indian J Ophthalmol. 2020;68:2291–2293.

30. Invernizzi A, Pellegrini M, Messenio D, et al. Impending central retinal vein occlusion in a patient with coronavirus disease 2019 (COVID-19). Ocul Immunol Inflamm. 2020;28:1290–1292.

31. Yahalomi T, Pikkel J, Arnon R, Pessach Y. Central retinal vein occlusion in a young healthy COVID-19 patient: a case report. Am J Ophthalmol Case Rep. 2020;20:100992.

32. Finn A, Khurana RN, Chang LK. Hemi-retinal vein occlusion in a young patient with COVID-19. Am J Case Rep. 2020;22:101046.

33. Rego Lorca D, Rouco Fernandez A, Jimenez Santos M, et al. Bilateral retinal vein occlusion and diabetic retinopathy after COVID-19. Acta Ophthalmol. 2021;99:e1246–e1248.

34. Miller CG, Kim BJ. Central retinal vein occlusion in a 46-year-old man with COVID-19: case report and review of the literature. Case Rep Ophthalmol. 2021;12:646–652.

35. Raval N, Djouagarian A, Lin J. Central retinal vein occlusion in the setting of COVID-19 infection. J Ophthal Inflamm Infect. 2021;11:10.

36. Cuadros Sánchez C, Egüen CS, Gutierrez-Esquerrro R, et al. Central retinal vein occlusion presumably associated with lupus anticoagulant induced by SARS-CoV-2. Ocul Immunol Inflamm. 2021 Jul 8;1-4. doi: 10.1080/09273948.2021.1933077. Online ahead of print.
37. Insauti-García A, Reche-Sainz JA, Ruiz-Arranz C, et al. Papillophlebitis in a COVID-19 patient: inflammation and hypercoagulable state. *Eur J Ophthalmol.* 2022;32: NP168–NP172.

38. McAllister IL. Central retinal vein occlusion: a review. *Clin Exp Ophthalmol.* 2012;40:48–58.

39. Jefferies P, Clement R, Day T. An anatomical study of retinal arteriovenous crossings and their role in the pathogenesis of retinal branch vein occlusions. *Aust N Z J Ophthalmol.* 1993;21:213–217.

40. Rudkin AK, Lee AW, Chen CS. Vascular risk factors for central retinal artery occlusion. *Eye (Lond)*. 2010;24:678–681.

41. Nagy V, Takacs L, Steiber Z, et al. Thrombophilic screening in retinal artery occlusion patients. *Clin Ophthalmol.* 2008;2:557–561.

42. Becker RC. COVID-19-associated vasculitis and vasculopathy. *J Thromb Thrombolysis.* 2020;50:499–511.

43. von Meijenfeldt FA, Havervall S, Adelmeijer J, et al. Prothrombotic changes in patients with COVID-19 are associated with disease severity and mortality. *Res Pract Thromb Haemost.* 2021;5:132–141.

44. von Meijenfeldt FA, Havervall S, Adelmeijer J, et al. Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge. *Blood Adv.* 2021;5:756–759.

45. Karimi S, Arabi A, Shahraki T, Saft S. Detection of severe acute respiratory syndrome Coronavirus-2 in the tears of patients with coronavirus disease 2019. *Eye (Lond).* 2020;34:1220–1223.

46. Casagrande M, Fitzek A, Püschel K, et al. Detection of SARS-CoV-2 in human retinal biopsies of deceased COVID-19 patients. *Ocul Immunol Inflamm.* 2020;28:721–725.

47. Araujo-Silva CA, Marcos AA, Marinho PM, et al. Presumed SARS-CoV-2 viral particles in the human retina of patients with COVID-19. *JAMA Ophthalmol.* 2021;139:1015–1021.

48. Central Vein Occlusion Study Group. Baseline and early natural history report the central vein occlusion study. *Arch Ophthalmol.* 1993;111:1087–1095.

49. Rothman AL, Thomas AS, Khan K, Fekrat S. Central retinal vein occlusion in young individuals: a comparison of risk factors and clinical outcomes. *Retina.* 2019;39:1917–1924.

50. Recchia FM, Carvalho-Recchia CA, Hassan TS. Clinical course of younger patients with central retinal vein occlusion. *Arch Ophthalmol.* 2004;122:317–321.

51. Sunny AC, Au CL. Prevalence of SARS-CoV-2 among central retinal vein occlusion patients. *Indian J Ophthalmol.* 2021;69:1355–1356.

52. David R, Zangwill L, Badarna M, Yassur Y. Epidemiology of retinal vein occlusion and its association with glaucoma and increased intraocular pressure. *Ophthalmologica.* 1988;197:69–74.

53. Klein R, Moss SE, Meuer SM, Klein BE. The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam eye study. *Arch Ophthalmol.* 2008;126:513–518.

54. Chen TY, Uppuluri A, Zarbin MA, Bhagat N. Risk factors for central retinal vein occlusion in young adults. *Eur J Ophthalmol.* 2021;31:2546–2555.

55. Nalcaci S, Degirmenci C, Akkin C, Mentes J. Etiological factors in young patients with retinal vein occlusion. *Pak J Med Sci.* 2019;35:1397–1401.

56. Fong AC, Schatz HH. Central retinal vein occlusion in young adults. *Surv Ophthalmol.* 1993;37:393–417.

57. Magargal LE, Gonder JR, Maher V. Central retinal vein obstruction in the young adult. *Trans Pa Acad Ophthalmol Otolaryngol.* 1985;37:148–153.

58. Rehak M, Rehak J, Müller M, et al. The prevalence of activated protein C (APC) resistance and factor V Leiden is significantly higher in patients with retinal vein occlusion without general risk factors. *Thromb Haemost.* 2008;99:925–929.

59. Sinawat S, Bunyavee C, Ratanapakorn T, et al. Systemic abnormalities associated with retinal vein occlusion in young patients. *Clin Ophthalmol.* 2017;11:441–447.

60. Walters RF, Spalton DJ. Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients. *Br J Ophthalmol.* 1990;74:30–35.

61. Lahey JM, Tunç M, Kearney J, et al. Laboratory evaluation of hypercoagulable states in patients with central retinal vein occlusion who are less than 56 years of age. *Ophthalmology.* 2002;109:126–131.